Abstract: This invention relates to stable capsule formulations for pharmaceutical, nutraceuticals or food supplements which contain thymoquinone (THQ) as an active ingredient, and which can be stored at room temperature without significant loss of THQ during the shelf life of the capsules. The preferred capsules have a hydroxypropylmethylcellulose (HPMC) shell and may contain carvacrol as an additional active ingredient, either in synthetic form, or as part of a plant extract. Optionally, the capsules may contain a viscosity agent.

Abstract: The present invention relates to the use of Nigella sp. extracts and their volatile components for the treatment of symptoms connected to impaired neurotransmission in animals including humans as well as to dietary supplements, food and feed or nutraceutical compositions containing such extracts or their volatile components.

Abstract: The present invention relates to the combination of a plant extract, such as oregano extract and a polyunsaturated fatty acid or a derivative (such as an ethyl ester “PUFA EE”) which is stable under strorage conditions.